<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-W8L21NJ5/4c2381c9-1fc4-4c72-b12f-efb2ea3e6b48/HTML"><dcterms:extent>44 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-W8L21NJ5/dfa8b647-3103-48f5-84b2-926e4660f9a0/PDF"><dcterms:extent>99 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-W8L21NJ5/c8f63dd0-6dd7-468d-ad88-fa6483b8b362/TEXT"><dcterms:extent>23 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-W8L21NJ5"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2009</dcterms:issued><dc:creator>Anderluh, Franc</dc:creator><dc:creator>Oblak, Irena</dc:creator><dc:creator>Velenik, Vaneja</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">letnik:43</dc:format><dc:format xml:lang="sl">str. 274-281</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:26682073</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-W8L21NJ5</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">Adenocarcinoma</dc:subject><dc:subject xml:lang="sl">Adenokarcinom</dc:subject><dc:subject xml:lang="en">Drug Therapy</dc:subject><dc:subject xml:lang="en">Gastrectomy</dc:subject><dc:subject xml:lang="sl">Gastrektomija</dc:subject><dc:subject xml:lang="en">Neoplasm Staging</dc:subject><dc:subject xml:lang="sl">Novotvorba, stadij</dc:subject><dc:subject xml:lang="sl">novotvorbe</dc:subject><dc:subject xml:lang="en">Pathology</dc:subject><dc:subject xml:lang="sl">preživetje</dc:subject><dc:subject xml:lang="sl">Preživetje, analiza</dc:subject><dc:subject xml:lang="sl">radiokemoterapija</dc:subject><dc:subject xml:lang="en">Radiotherapy</dc:subject><dc:subject xml:lang="en">Stomach Neoplasms</dc:subject><dc:subject xml:lang="en">Surgery</dc:subject><dc:subject xml:lang="en">Survival Analysis</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">tumor</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dc:subject xml:lang="sl">želodec</dc:subject><dc:subject xml:lang="sl">Želodec, novotvorbe</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Postoperative radiochemotherapy for gastric adenocarcinoma| long term results|</dc:title><dc:description xml:lang="sl">Background. To analyze the efficacy of postoperative radiochemotherapy with 5-florouracil (5-FU) and leucovorin (LV) applied in the patients with gastric carcinoma treated in a single institution. Patients and methods. Between 2001 and 2004, 123 patients with resected gastric adenocarcinoma were treated with postoperative concomitant radiochemotherapy with 5-FU and LV. The adjuvant treatment consisted of five cycles of chemotherapy with 5-FU (425mg/m2 IV) andLV (20 mg/m2 IV) and concomitant radiotherapy with the total dose of 45 Gy.Results. The treatment was completed according to the protocol in 82% of patients. The frequency and severity of early toxic effects induced by radiochemotherapy were manageable. Median follow-up time of 56 survivors was 64.5 months (range: 51.7-96.4 months). The 5-year locoregional control (LRC), diseasefree survival (DFS), disease-specific survival (DSS) and overall survival (OS) were 81%, 48.3%, 50.4%, and 48.4%, respectively. The multivariate analysis showed that the tumor involvement of cardia and low intensity of chemotherapy were independent adverse prognostic factors for DSS and OS. More advanced pT-stage and tumors with diffuse growth type according to Lauren were identified as negative independent prognostic factor for OS. They were also on the threshold of statistical significance for DSS. Conclusions. Postoperative radiochemotherapy for gastric carcinoma has acceptable toxicity, and is effective particularly in regard to LRC. High incidence of distant metastases calls for more effective systemic regimens</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-W8L21NJ5"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-W8L21NJ5" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-W8L21NJ5/dfa8b647-3103-48f5-84b2-926e4660f9a0/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-W8L21NJ5/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-W8L21NJ5" /></ore:Aggregation></rdf:RDF>